PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2022 Financial Results

Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB) will release its first quarter 2022 financial results on May 11, 2022, before market opening. Management will host a conference call at 8:00 AM EDT to discuss results and provide a business update. PDS Biotech focuses on developing molecularly targeted cancer therapies and infectious disease vaccines using its proprietary Versamune^® and Infectimune™ technologies. The company aims to enhance T-cell responses to effectively target and destroy diseased cells.

Positive

• Upcoming conference call on May 11 to discuss financial results and business updates.
• Focus on innovative cancer therapies and infectious disease vaccines.

Negative

• None.

FLORHAM PARK, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing molecularly targeted cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune^® and Infectimune™ T-cell activating technologies, today announced that the Company will release financial results for the first quarter of 2022 on Wednesday, May 11, 2022, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.

Wednesday, May 11, 2022, 8:00 AM EDT
Domestic: 877-407-3088
International: 201-389-0927
Conference ID: 13728184
Webcast: PDS Biotech Earnings Webcast

After the live webcast, the event will be archived on PDS Biotech’s website for six months.

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune^® and Infectimune™ T-cell activating technology platforms.

Our Versamune^®-based molecularly targeted products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune^® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate, and ovarian cancers. 

Our Infectimune™-based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
pdsb@cg.capital

FAQ

When will PDSB release its first quarter 2022 financial results?

PDSB will release its first quarter 2022 financial results on May 11, 2022, before the market opens.

What time is the PDSB conference call for financial results?

The PDSB conference call will take place at 8:00 AM EDT on May 11, 2022.

What technologies does PDSB use in its therapies?

PDSB uses its proprietary Versamune^® and Infectimune™ technologies for developing cancer therapies and vaccines.

What type of cancer does PDSB target?

PDSB targets various cancers, including HPV16-associated cancers, breast, colon, lung, prostate, and ovarian cancers.